Induction therapy regimens
| Therapy type . |
|---|
| Stem cell–sparing |
| Dexamethasone |
| Thalidomide and dexamethasone or prednisone; with or without cyclophosphamide or doxorubicin |
| Bortezomib and dexamethasone or prednisone; with or without thalidomide or doxorubicin |
| Lenalidomide* and low-dose dexamethasone or prednisone |
| Non-stem cell–sparing |
| Melphalan-prednisone (MP) |
| Melphalan-prednisone-thalidomide (MPT) |
| Melphalan-prednisone-bortezomib (MPB) |
| Melphalan-prednisone-lenalidomide (MPL) |
| Therapy type . |
|---|
| Stem cell–sparing |
| Dexamethasone |
| Thalidomide and dexamethasone or prednisone; with or without cyclophosphamide or doxorubicin |
| Bortezomib and dexamethasone or prednisone; with or without thalidomide or doxorubicin |
| Lenalidomide* and low-dose dexamethasone or prednisone |
| Non-stem cell–sparing |
| Melphalan-prednisone (MP) |
| Melphalan-prednisone-thalidomide (MPT) |
| Melphalan-prednisone-bortezomib (MPB) |
| Melphalan-prednisone-lenalidomide (MPL) |
Exposure to more than 3 to 6 cycles of lenalidomide, particularly in elderly patients, can result in difficulty in collecting stem cells. It is therefore better to collect stem cells early in patients receiving lenalidomide. The use of chemotherapy- or plerixafor-containing mobilization regimens increases the likelihood of a successful stem cell collection in lenalidomide-treated patients.